0
Reviews
Safety Issues with Statin Therapy
Robert L. Talbert, PharmD
J Am Pharm Assoc (2003) 2006;46:479-490. doi:10.1331/154434506778073637

Abstract

Objective  To describe the most important potential adverse effects related to statin therapy, discuss mechanisms of toxicity and drug interactions, and suggest approaches for enhancing safety with statin therapy.

Data Sources  Large-scale clinical trials, government databases and papers, and recent studies of statin safety.

Study Selection  By the author.

Data Extraction  By the author.

Data Synthesis  The number of patients requiring intensive therapy with statins to achieve lipid goals is climbing, and as the number grows, so does the potential for adverse effects with these agents. The most detrimental adverse effects of statins are hepatotoxicity and myopathy. Liver dysfunction induced by statins is rare and usually mild, with asymptomatic transaminase elevation or acute cholecystitis. Progression to liver failure is exceedingly rare, and transaminase elevations is usually reversible with dose reduction. Statin-associated myopathy is generally a concern when patients have more than one risk factor for muscle syndromes, such as an elderly patient with poor renal function. Drug interactions represent an additional concern, especially for atorvastatin, lovastatin, and simvastatin, all of which are metabolized by the important 3A4 isoenzyme of the cytochrome P450 system of the liver.

Conclusion  The benefits of all available statins for the treatment or prevention of cardiovascular disease outweigh any potential risks of therapy. For patient groups most susceptible to adverse effects, such as the elderly and those on multiple medications, clinicians should consider the use of statins that are least likely to interact with other medications.

Topics

statins
Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

 American Heart Association. Heart disease and stroke statistics—2005 update. Dallas, Tex.:  American Heart Association;  2005.
 
Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III guidelines for primary prevention lipid-lowering drug therapy: projected impact on the size, sex, and age distribution of the treatment-eligible population. Circulation. 2002;105:152–6.[PubMed][CrossRef]
 
 The Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–421.[PubMed]
 
Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.[PubMed]
 
Cannon CP, Braunwald E, McCabe CH, et al., for the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–504.[PubMed]
 
 Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.[PubMed]
 
LaRosa JC, Grundy SM, Waters DD, et al.,  for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.[PubMed]
 
Grundy SM, Cleeman JI, Bairey Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–39.[PubMed]
 
Pasternak RC, Smith SC Jr., Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke. 2002;33:2337–41.[PubMed]
 
Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol. 2003;92:670–6.[PubMed]
 
Jones PH, Davidson MH, Stein EA, et al.,  for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol. 2003;92:152–60.[PubMed]
 
Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413–28.[PubMed]
 
Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation. 2004;109(suppl III):III-50–III-57.
 
Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism—monograph for physicians. Arch Intern Med. 2000;160:2273–80.[PubMed]
 
Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci. 1998;19:26–37.[PubMed]
 
Sica DA, Gehr TWB. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol. 2002;11:48–55.[PubMed]
 
Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553–64.[PubMed]
 
McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyulglutaryl coenzyme A reductase inhibitor. A M Cardiol. 2001;87(suppl):28B–32B.
 
 Crestor [package insert]. Wilmington, Del.:  AstraZeneca Pharmaceuticals LP; March  2005.
 
 Lescol [package insert]. East Hanover, N.J.:  Novartis Pharmaceuticals Corp.; May  2003.
 
 Lipitor [package insert]. New York:  Pfizer Inc; July  2004.
 
 Pravachol [package insert]. Princeton, N.J.:  Bristol-Myers Squibb Co; December  2004.
 
 Zocor [package insert]. Whitehouse Station, N.J.:  Merck & Co; November  2004.
 
Cavallari LH, Lam YWF. Pharmacogenomics. In: DiPiro JT, Talbert RL, Wells BG, et al., eds.  Pharmacotherapy: a pathophysiologic approach.6th ed. New York:  McGraw-Hill;  2005:75–90.
 
Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol. 2004;94:1140–6.[PubMed]
 
Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48–56.[PubMed]
 
Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics. 1997;7:193–202.[PubMed]
 
Kanathur N, Mathai MG, Byrd RP Jr., et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tennessee Med. 2001;94:339–41.
 
Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl. 2002;3:35–40.[PubMed]
 
Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant. 1996;11:1846–7.[PubMed]
 
Gladding P, Pilmore H, Edwards C. Potentially fatal interaction between diltiazem and statins. Ann Intern Med. 2004;140:20.
 
Kasbekar N, Acharya PS. Telithromycin: the first ketolide for the treatment of respiratory infection. Am J Health Syst Pharm. 2005;62:905–16.[PubMed]
 
Rätz Bravo AE, Tchambaz L, Krähenbıhl-Melcher A, et al. Prevalence of potentially severe drug–drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. Drug Saf. 2005;28:263–75.[PubMed]
 
Einarson TR, Metge CJ, Iskedjian M, Mukherjee J. An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clin Ther. 2002;24:2126–36.[PubMed]
 
Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins [letter]. Arch Intern Med. 2003;163:2393–4.
 
Prueksaritanont T, Tang C, Qiu Y, et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002;30:1280–7.[PubMed]
 
Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther. 2004;75:455–63.[PubMed]
 
Hsiang B, Zhu Y, Wang Z, et al. A novel human hepatic organic anion transporting polypeptide (OATP2): identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999;274:37161–8.[PubMed]
 
Mwinyi J, Johne A, Bauer S, et al. Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther. 2004;75:415–21.[PubMed]
 
Nishizato Y, Ieiri I, Suzuki H, et al. Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther. 2003; 73:554–65.[PubMed]
 
Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004;76:167–77.[PubMed]
 
Martin PD, Dane AL, Schneck DW, Warwick MJ. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther. 2003;25:459–71.[PubMed]
 
Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343–70.[PubMed]
 
Vlahakos DV, Manginas A, Chilidou D, et al. Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine. Transplantation. 2002;73:1962–4.[PubMed]
 
Barshes NR, Goodpastor SE, Goss JA, DeBakey ME. Sirolimus–atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation. 2003;76:1649–50.[PubMed]
 
Schonder KS, McKaveney TP, Lynch KJ. Retrospective analysis of hyperlipidemia management in a transplant population. Pharmacotherapy. 2005;25:918–23.[PubMed]
 
Smith CC, Bernstein LI, Davis RB, et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003;163:688–92.[PubMed]
 
Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch Intern Med. 2003;163:657–9.[PubMed]
 
Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000;23:197–213.[PubMed]
 
Andrade SE, Donahue JG, Chan KA, et al. Liver function testing in patients on HMG-CoA reductase inhibitors. Pharmacoepidemiol Drug Saf. 2003;12:307–13.[PubMed]
 
Cressman MD, Hoogwerf BJ, Moodie DS, et al. HMG-CoA reductase inhibitors: a new approach to the management of hypercholesterolemia. Cleve Clin J Med. 1988;55:93–100.[PubMed]
 
 Vytorin [package insert]. North Wales, Pa.:  Merck/Schering-Plough Pharmaceuticals; March  2005.
 
Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002;4:34–41.[PubMed]
 
Jimenez-Alonso J, Osorio JM, Gutierrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med. 1999;159:1811–2.[PubMed]
 
Pelli N, Setti M, Ceppa P, et al. Autoimmune hepatitis revealed by atorvastatin. Eur J Gastroenterol Hepatol. 2003;15:921–4.[PubMed]
 
Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–90.[PubMed]
 
Jacobson TA. Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. Expert Opin Drug Saf. 2003;2:269–86.[PubMed]
 
Warren JD, Blumbergs PC, Thompson PD. Rhabdomyolysis: a review. Muscle Nerve. 2002; 25:332–47.[PubMed]
 
Andrade SE, Graham DJ, Staffa JA, et al. Health plan administrative databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin Epidemiol. 2005;58:171–4.[PubMed]
 
Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292:2585–90.[PubMed]
 
Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288–95.[PubMed]
 
Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417–26.[PubMed]
 
Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539–40.[PubMed]
 
Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) project. Circulation. 2002;105:2341–6.[PubMed]
 
Downs JR, Clearfield M, Tyroler HA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol. 2001;87:1074–9.[PubMed]
 
 Food and Drug Administration. FDA response to a citizen petition regarding Crestor (March 11, 2005). Accessed at www.fda.gov/cder/drug/infopage/rosuvastatin/crestor_CP.pdf, April 24,  2005.
 
Davidson MH. Combination therapy for dyslipidemia: safety and regulatory considerations. Am J Cardiol. 2002;90(suppl 10B):50K–60K.[PubMed]
 
Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18(suppl):S137–44.[PubMed]
 
Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002;137:581–5.[PubMed]
 
Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. Expert Opin Drug Saf. 2004;3:547–57.[PubMed]
 
Agarwal R. Statin induced proteinuria: renal injury or renoprotection? J Am Soc Nephrol. 2004;15:2502–3.[PubMed]
 
Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy: a case–control study. Neurology. 2002;58:1333–7.[PubMed]
 
Ehrenberg BL, Lamon-Fava S, Corbett KE, et al. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep. 1999;22:117–21.[PubMed]
 
Bohm M, Herrmann W, Wassmann S, et al. Does statin therapy influence steroid hormone synthesis? Z Kardiol. 2004;93:43–8.[PubMed]
 
Ormiston T, Wolkowitz OM, Reus VI, et al. Hormonal changes with cholesterol reduction: a double-blind pilot study. J Clin Pharm Ther. 2004;29:71–3.[PubMed]
 
Lee EJ, Ryan S, Birmingham BK, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330–41.[PubMed]
 
 A symposium: report of the National Lipid Association's Statin Safety Task Force. Am J Cardiol. 2006;97(suppl 8A):1C–97C.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints